Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence

Overview

Journal Front Oncol

Specialty Oncology

Date 2016 Dec 20

PMID 27990412

Citations 21

Authors

Malgorzata Banys-Paluchowski

Natalia Krawczyk

Tanja Fehm

Affiliations

Soon will be listed here.

Abstract

The phenomenon of hematogenous tumor cell dissemination in patients with solid tumors has been extensively explored over the last decades. Breast cancer research investigated at first disseminated tumor cells in the bone marrow; however, the focus soon moved to circulating tumor cells (CTCs) in the peripheral blood as blood is easily accessible without an invasive procedure. The prognostic significance of CTC presence has been shown in large studies both in adjuvant and metastatic setting and commercially available detection assays have been evaluated for monitoring in clinical trials. Beyond detection and enumeration of CTCs, the characterization of single tumor cells may enhance our knowledge on disease progression and thus optimize treatment choices.

Citing Articles

The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer.

Wang L, Hong R, Shi S, Wang S, Chen Y, Han C BMC Cancer. 2024; 24(1):1067.

PMID: 39210288 PMC: 11360297. DOI: 10.1186/s12885-024-12818-1.

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.

Kotsifaki A, Maroulaki S, Armakolas A Int J Mol Sci. 2024; 25(9).

PMID: 38732051 PMC: 11084220. DOI: 10.3390/ijms25094832.

Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).

Gao L, Medford A, Spring L, Bar Y, Hu B, Jimenez R Breast Cancer Res Treat. 2024; 205(2):211-226.

PMID: 38355821 DOI: 10.1007/s10549-024-07253-6.

An Image-Based Identification of Aggressive Breast Cancer Circulating Tumor Cell Subtypes.

Kamal M, Wang Y, Plummer S, Dickerson A, Yu M Cancers (Basel). 2023; 15(10).

PMID: 37345005 PMC: 10216536. DOI: 10.3390/cancers15102669.

Circulating Tumor-Derived Endothelial Cells: An Effective Biomarker for Breast Cancer Screening and Prognosis Prediction.

Han T, Zhang J, Xiao D, Yang B, Chen L, Zhai C J Oncol. 2022; 2022:5247423.

PMID: 36072971 PMC: 9441390. DOI: 10.1155/2022/5247423.

References

Lucci A, Hall C, Lodhi A, Bhattacharyya A, Anderson A, Xiao L . Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012; 13(7):688-95. DOI: 10.1016/S1470-2045(12)70209-7. View

Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann E . Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013; 73(10):2965-75. DOI: 10.1158/0008-5472.CAN-12-4140. View

Banys-Paluchowski M, Schneck H, Blassl C, Schultz S, Meier-Stiegen F, Niederacher D . Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. Geburtshilfe Frauenheilkd. 2015; 75(3):232-237. PMC: 4397936. DOI: 10.1055/s-0035-1545788. View

Olkhanud P, Baatar D, Bodogai M, Hakim F, Gress R, Anderson R . Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009; 69(14):5996-6004. PMC: 2743688. DOI: 10.1158/0008-5472.CAN-08-4619. View

Wulfing P, Borchard J, Buerger H, Heidl S, Zanker K, Kiesel L . HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006; 12(6):1715-20. DOI: 10.1158/1078-0432.CCR-05-2087. View

Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T . Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5). PMC: 4112925. DOI: 10.1093/jnci/dju066. View

Wallwiener M, Hartkopf A, Baccelli I, Riethdorf S, Schott S, Pantel K . The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat. 2012; 137(2):503-10. DOI: 10.1007/s10549-012-2382-0. View

Kasimir-Bauer S, Bittner A, Konig L, Reiter K, Keller T, Kimmig R . Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 2016; 18(1):20. PMC: 4751719. DOI: 10.1186/s13058-016-0679-3. View

Ignatiadis M, Rack B, Rothe F, Riethdorf S, Decraene C, Bonnefoi H . Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. Eur J Cancer. 2016; 63:97-104. DOI: 10.1016/j.ejca.2016.04.024. View

10.

Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D . Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15(4):406-14. DOI: 10.1016/S1470-2045(14)70069-5. View

11.

Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N . Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2009; 17(3):199-204. DOI: 10.1007/s12282-009-0139-3. View

12.

Smerage J, Barlow W, Hortobagyi G, Winer E, Leyland-Jones B, Srkalovic G . Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014; 32(31):3483-9. PMC: 4209100. DOI: 10.1200/JCO.2014.56.2561. View

13.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M . Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol. 2007; 25(33):5194-202. DOI: 10.1200/JCO.2007.11.7762. View

14.

Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer E, Wallwiener D . Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009; 11(4):R59. PMC: 2750121. DOI: 10.1186/bcr2349. View

15.

Bidard F, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P . Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2009; 21(4):729-733. DOI: 10.1093/annonc/mdp391. View

16.

Kuniyoshi R, Gehrke F, Alves B, Vilas-Boas V, Colo A, Sousa N . Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer. Tumour Biol. 2015; 36(10):8075-83. DOI: 10.1007/s13277-015-3529-5. View

17.

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

18.

De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S . Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016; 7(18):26107-19. PMC: 5041968. DOI: 10.18632/oncotarget.8431. View

19.

Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M . Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin Breast Cancer. 2008; 7(11):883-9. DOI: 10.3816/CBC.2007.n.054. View

20.

Bidard F, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L . Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol. 2008; 19(3):496-500. DOI: 10.1093/annonc/mdm507. View